Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CTMX

CytomX Therapeutics Inc

Dec 05 • 04:00PM ET

1.16

Dollar change -0.13
Percentage change -10.08	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE PRTA SRRK IMTX AFMD RCUS RNA XBIT ALXO PIRS

| Held by: VTI VXF FORH FESM IWC QQQS

Scroll to Statements

Index	-	P/E	6.84	EPS (ttm)	0.17	Insider Own	1.69%	Shs Outstand	78.23M	Perf Week	13.73%
Market Cap	90.78M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-2.10%	Shs Float	76.93M	Perf Month	16.82%
Income	13.83M	PEG	-	EPS next Q	-0.20	Inst Own	65.49%	Short Float	5.77%	Perf Quarter	-3.33%
Sales	126.62M	P/S	0.72	EPS this Y	-328.04%	Inst Trans	1.30%	Short Ratio	4.12	Perf Half Y	-30.54%
Book/sh	-0.30	P/B	-	EPS next Y	-908.36%	ROA	7.68%	Short Interest	4.44M	Perf Year	-17.73%
Cash/sh	1.50	P/C	0.77	EPS next 5Y	-0.90%	ROE	-	52W Range	0.83 - 5.85	Perf YTD	-25.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.21%	ROI	-	52W High	-80.17%	Beta	1.03
Dividend TTM	-	Quick Ratio	1.04	Sales past 5Y	28.25%	Gross Margin	98.55%	52W Low	39.26%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.04	EPS Y/Y TTM	205.69%	Oper. Margin	5.30%	RSI (14)	58.74	Volatility	12.75% 9.17%
Employees	122	Debt/Eq	-	Sales Y/Y TTM	33.66%	Profit Margin	10.92%	Recom	2.00	Target Price	5.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	82.38%	Payout	-	Rel Volume	1.47	Prev Close	1.29
Sales Surprise	95.51%	EPS Surprise	140.63%	Sales Q/Q	26.71%	Earnings	Nov 07 AMC	Avg Volume	1.08M	Price	1.16
SMA20	14.27%	SMA50	8.57%	SMA200	-26.26%	Trades		Volume	1,583,036	Change	-10.08%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight	$2.25 → $3.50
May-09-24	Upgrade	Wedbush	Neutral → Outperform	$8
May-06-24	Upgrade	Jefferies	Hold → Buy	$2.50 → $8
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$3 → $2.60
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral	$6 → $2
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $1.50
Jul-07-22	Downgrade	Mizuho	Buy → Neutral	$16 → $4
Jul-07-22	Downgrade	Jefferies	Buy → Hold	$12 → $2
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$9
Jan-18-22	Upgrade	Barclays	Underweight → Overweight	$7
Nov-15-21	Initiated	BTIG Research	Buy	$16
May-28-21	Downgrade	Barclays	Equal Weight → Underweight	$9 → $7
Mar-29-21	Initiated	JP Morgan	Overweight	$14
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold	$16 → $10
May-14-20	Reiterated	H.C. Wainwright	Buy	$16 → $12
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight	$7

Show Previous Ratings

Nov-27-24 08:00AM	CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 09:35AM	Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 11:54AM	Q3 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.00%
02:32AM	CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 05:55PM	CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:49PM	Loading…
04:49PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 07:52AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result (GuruFocus.com)
Oct-31-24 08:00AM	CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-09-24 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors (GlobeNewswire)
Sep-04-24 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +11.61%
Aug-10-24 08:18AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-08-24 09:56PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:46PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Aug-01-24 08:00AM	CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-25-24 02:26AM	CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-18-24 08:00AM	CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -5.84%
Jun-17-24 04:15PM	CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer (GlobeNewswire)
Jun-05-24 06:00AM	Buy Alert: 3 Penny Stocks That Will Explode in 2024 (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-29-24 06:25AM	No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock. (InvestorPlace)
May-22-24 04:05PM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 04:15PM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -5.50%
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
May-09-24 04:17PM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript (Insider Monkey) -51.31%
11:56AM	Why Is CytomX (CTMX) Stock Down 43% Today? (InvestorPlace)
11:32AM	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating (MT Newswires)
08:12AM	Q1 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:48AM	Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3 (MT Newswires)
07:29AM	Loading…
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
04:01AM	CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:58PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager) (GlobeNewswire)
May-07-24 04:15PM	CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -6.86%
May-06-24 07:09AM	Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8 (MT Newswires)
May-02-24 08:08AM	CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-01-24 12:11PM	Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally (InvestorPlace) +214.72%
11:43AM	Why Is CytomX (CTMX) Stock Up 180% Today? (InvestorPlace)
08:00AM	CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
Apr-03-24 08:00AM	CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-21-24 08:00AM	CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors (GlobeNewswire)
Mar-18-24 08:00AM	CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-12-24 09:12AM	Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today? (InvestorPlace) -14.34%
08:30AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:46AM	Q4 2023 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-24 05:34PM	CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update (GuruFocus.com)
05:20PM	CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates (Zacks)
04:10PM	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-24 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 (GlobeNewswire)
Feb-27-24 11:52AM	CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect (Zacks) +36.36%
08:00AM	CytomX Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Jan-24-24 08:00AM	CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b (GlobeNewswire)
Jan-12-24 08:00AM	CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference (GlobeNewswire)
Jan-04-24 08:00AM	CytomX Therapeutics Outlines 2024 Company Priorities and Milestones (GlobeNewswire)
Dec-21-23 08:00AM	CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.22%
Nov-13-23 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.13%
Nov-08-23 10:15AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:05PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-23 08:00AM	CytomX Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 08:00AM	CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting (GlobeNewswire)
Oct-18-23 04:30PM	CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference (GlobeNewswire)
Sep-05-23 04:05PM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) -5.33%
Aug-25-23 09:35AM	CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-10-23 04:05PM	CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-08-23 05:30PM	CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 08:00AM	CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-20-23 09:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-17-23 08:00AM	CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (GlobeNewswire)
Jun-30-23 08:00AM	CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P. (GlobeNewswire) +21.99%
Jun-08-23 09:02AM	CytomX Therapeutics (NASDAQ:CTMX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-01-23 04:05PM	CytomX Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 06:05AM	CytomX Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:13AM	Q1 2023 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +5.81%
May-09-23 05:35PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:26PM	CytomX Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:15PM	CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-05-23 06:34AM	CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-01-23 04:01PM	CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire) +5.52%
10:01AM	Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-27-23 10:03AM	Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-25-23 04:05PM	CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-30-23 11:26AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 06:06AM	What Does The Future Hold For CytomX Therapeutics, Inc. (NASDAQ:CTMX)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Mar-28-23 01:35PM	AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners (Benzinga) -15.08%
Mar-27-23 05:35PM	CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.29%
04:15PM	CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-22-23 07:23PM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 (GlobeNewswire)
Mar-20-23 06:14AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 42% of the company (Simply Wall St.)
Feb-28-23 04:05PM	CytomX Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-07-23 06:07AM	Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago (Simply Wall St.)
Jan-26-23 07:00AM	CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire) +6.11%

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	123,237	Aug 22 06:01 PM
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Sale	1.23	4,181	5,139	119,056	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	179,829	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Sale	1.23	4,181	5,139	175,648	Aug 22 06:01 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Option Exercise	0.00	11,250	0	134,978	Aug 22 06:00 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Sale	1.23	4,181	5,139	130,797	Aug 22 06:00 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Option Exercise	0.00	6,875	0	110,061	Aug 22 05:59 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Sale	1.23	1,984	2,439	108,077	Aug 22 05:59 PM
McCarthy Sean A.	CEO	Aug 20 '24	Option Exercise	0.00	37,500	0	671,749	Aug 22 05:58 PM
McCarthy Sean A.	CEO	Aug 20 '24	Sale	1.23	13,898	17,082	657,851	Aug 22 05:58 PM
McCarthy Sean A.	CEO	Mar 26 '24	Option Exercise	1.57	109,768	172,874	634,249	Mar 28 07:12 PM
ROWLAND LLOYD A	General Counsel	Mar 19 '24	Sale	2.09	5,268	10,986	117,728	Mar 21 04:41 PM
McCarthy Sean A.	CEO	Mar 19 '24	Sale	2.09	20,223	42,175	524,481	Mar 21 04:40 PM
Ogden Christopher	SVP, Finance and Accounting	Mar 19 '24	Sale	2.09	2,971	6,196	85,686	Mar 21 04:38 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 19 '24	Sale	2.09	12,795	26,684	168,579	Mar 21 04:37 PM
Landau Jeffrey B	Chief Business Officer	Mar 19 '24	Sale	2.09	6,562	13,685	110,060	Mar 21 04:36 PM
McCarthy Sean A.	CEO	Dec 20 '23	Sale	1.38	13,551	18,710	454,704	Dec 22 04:16 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Dec 20 '23	Sale	1.38	4,077	5,628	155,124	Dec 22 04:14 PM
Landau Jeffrey B	Chief Business Officer	Dec 20 '23	Sale	1.38	4,077	5,628	86,622	Dec 22 04:12 PM
ROWLAND LLOYD A	General Counsel	Dec 20 '23	Sale	1.38	4,077	5,629	97,996	Dec 22 04:11 PM
Ogden Christopher	SVP, Finance and Accounting	Dec 20 '23	Sale	1.38	1,990	2,747	48,657	Dec 22 04:10 PM
Ogden Christopher	SVP, Finance and Accounting	Dec 17 '23	Option Exercise	0.00	6,875	0	50,647	Dec 19 07:58 PM
McCarthy Sean A.	CEO	Dec 17 '23	Option Exercise	0.00	37,500	0	468,255	Dec 19 07:57 PM
Landau Jeffrey B	Chief Business Officer	Dec 17 '23	Option Exercise	0.00	11,250	0	90,699	Dec 19 07:56 PM
ROWLAND LLOYD A	General Counsel	Dec 17 '23	Option Exercise	0.00	11,250	0	102,073	Dec 19 07:55 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Dec 17 '23	Option Exercise	0.00	11,250	0	159,201	Dec 19 07:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX

CytomX Therapeutics Inc

Upgrade your FINVIZ experience